The global Duchenne muscular dystrophy (DMD) drugs market size was estimated to be USD 2.96 billion in 2023 and is expected to reach USD 111.36 billion by 2034 with a CAGR of 39.12% during the forecast period 2024-2034. The increasing prevalence of Duchenne muscular dystrophy, advancements in genetic research, gene therapy, and genetic editing technologies, government initiatives and support, increased collaboration and partnerships, and technological advancements in drug delivery will drive market growth.
Finding viable treatments and therapies has been a major driving force behind research and development efforts due to the increasing frequency of DMD. Novel therapeutic approaches for genetic diseases such as DMD have become possible with the advent of gene therapy and genetic editing technology. For instance, in October 2023, ambulatory boys with Duchenne mutations susceptible to skipping exons 45-50 had good preliminary findings from the Phase 3 PROMINENCE trial assessing SRP-9041, a next-generation exon skipping option.
By drug type, the corticosteroids segment accounted for the highest revenue-grossing segment in the global Duchenne muscular dystrophy (DMD) drugs market in 2023 owing to the significant efficacy demonstrated in managing inflammation and delaying disease progression, along with the established track record of corticosteroids, such as prednisone and deflazacort, as a standard-of-care treatment for Duchenne Muscular Dystrophy (DMD). For instance, PTC Therapeutics announced in November 2023 the start of the Phase 2b PULSAR project, which will assess PTC518-a next-generation nonsense mutation treatment candidate-in conjunction with Ataluren in patients with Duchenne who have nonsense mutations. Additionally, the exon-skipping therapies segment is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in precision medicine, significant research and development investments, and the increasing adoption of exon-skipping therapies, such as Eteplirsen, Golodirsen, and Viltolarsen, which have demonstrated promising outcomes in treating specific genetic mutations associated with Duchenne Muscular Dystrophy (DMD).
By distribution channel, the hospital's segment accounted for the highest revenue-grossing segment in the global Duchenne muscular dystrophy (DMD) drugs market in 2023 owing to the established infrastructure and specialized medical facilities available in hospitals, facilitating the diagnosis, treatment, and management of Duchenne Muscular Dystrophy (DMD). For instance, Pfizer Inc. presented encouraging results from the Phase 3 DELOS investigation in October 2023, indicating that Vyondys 53 continues to be safe and effective in ambulatory boys with Duchenne mutations who are able to skip exons 53-55. Additionally, the specialty pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on personalized patient care, improved accessibility to orphan drugs, and the rising trend of home-based treatments for Duchenne Muscular Dystrophy (DMD).
North American region is anticipated to have the highest revenue share during the forecast period owing to the robust healthcare infrastructure, extensive research and development activities, and a well-established regulatory framework for drug approvals. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of Duchenne Muscular Dystrophy (DMD), a growing patient population, and rising investments in healthcare infrastructure and research and development. For instance, in September 2023, the European Commission permitted Santhera Pharmaceuticals to commercialize idebenone to treat muscular weakness in ambulatory Duchenne patients six years of age and older.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Finding viable treatments and therapies has been a major driving force behind research and development efforts due to the increasing frequency of DMD. Novel therapeutic approaches for genetic diseases such as DMD have become possible with the advent of gene therapy and genetic editing technology. For instance, in October 2023, ambulatory boys with Duchenne mutations susceptible to skipping exons 45-50 had good preliminary findings from the Phase 3 PROMINENCE trial assessing SRP-9041, a next-generation exon skipping option.
By drug type, the corticosteroids segment accounted for the highest revenue-grossing segment in the global Duchenne muscular dystrophy (DMD) drugs market in 2023 owing to the significant efficacy demonstrated in managing inflammation and delaying disease progression, along with the established track record of corticosteroids, such as prednisone and deflazacort, as a standard-of-care treatment for Duchenne Muscular Dystrophy (DMD). For instance, PTC Therapeutics announced in November 2023 the start of the Phase 2b PULSAR project, which will assess PTC518-a next-generation nonsense mutation treatment candidate-in conjunction with Ataluren in patients with Duchenne who have nonsense mutations. Additionally, the exon-skipping therapies segment is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in precision medicine, significant research and development investments, and the increasing adoption of exon-skipping therapies, such as Eteplirsen, Golodirsen, and Viltolarsen, which have demonstrated promising outcomes in treating specific genetic mutations associated with Duchenne Muscular Dystrophy (DMD).
By distribution channel, the hospital's segment accounted for the highest revenue-grossing segment in the global Duchenne muscular dystrophy (DMD) drugs market in 2023 owing to the established infrastructure and specialized medical facilities available in hospitals, facilitating the diagnosis, treatment, and management of Duchenne Muscular Dystrophy (DMD). For instance, Pfizer Inc. presented encouraging results from the Phase 3 DELOS investigation in October 2023, indicating that Vyondys 53 continues to be safe and effective in ambulatory boys with Duchenne mutations who are able to skip exons 53-55. Additionally, the specialty pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on personalized patient care, improved accessibility to orphan drugs, and the rising trend of home-based treatments for Duchenne Muscular Dystrophy (DMD).
North American region is anticipated to have the highest revenue share during the forecast period owing to the robust healthcare infrastructure, extensive research and development activities, and a well-established regulatory framework for drug approvals. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of Duchenne Muscular Dystrophy (DMD), a growing patient population, and rising investments in healthcare infrastructure and research and development. For instance, in September 2023, the European Commission permitted Santhera Pharmaceuticals to commercialize idebenone to treat muscular weakness in ambulatory Duchenne patients six years of age and older.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Drug Type, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Duchenne Muscular Dystrophy (DMD) Drugs Market Report 2023 - 2034
Duchenne Muscular Dystrophy (DMD) Drugs Market Analysis & Forecast by Drug Type 2023 - 2034 (Revenue USD Bn)
- Corticosteroids
- Exon Skipping Therapies
- Nonsense Mutation Therapies
- Gene Therapy
- Myostatin Inhibitors
Duchenne Muscular Dystrophy (DMD) Drugs Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Specialty Pharmacies
- Others
Duchenne Muscular Dystrophy (DMD) Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Duchenne Muscular Dystrophy (DMD) Drugs Market: Drug Type Estimates & Trend Analysis
8. Duchenne Muscular Dystrophy (DMD) Drugs Market: Distribution Channel Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Duchenne Muscular Dystrophy (DMD) Drugs Market
11. Europe Global Duchenne Muscular Dystrophy (DMD) Drugs Market
12. Asia Pacific Global Duchenne Muscular Dystrophy (DMD) Drugs Market
13. Latin America Global Duchenne Muscular Dystrophy (DMD) Drugs Market
14. MEA Global Duchenne Muscular Dystrophy (DMD) Drugs Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Sarepta Therapeutics
- Pfizer Inc.
- Santhera Pharmaceuticals
- PTC Therapeutics
- Summit Therapeutics
- Catabasis Pharmaceuticals
- CureDuchenne
- Capricor Therapeutics
- Wave Life Sciences
- NS Pharma (Nippon Shinyaku)
- Solid Biosciences
- Beech Tree Labs
- Roche (Genentech)
- Avidity Biosciences
- Acceleron Pharma.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.96 Billion |
| Forecasted Market Value ( USD | $ 111.36 Billion |
| Compound Annual Growth Rate | 39.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
